Safety and efficacy of Yupingfeng granules in children with recurrent respiratory tract infection: A randomized clinical trial
Xu B, Li X, Hu S, Bao Y, Chen F, Chen Z, Du Y, Liu E, Liu Y, Mou Q, Su B, Wang B, Xu J, Xu G, Yang Q, Gao L, Liu X, Li L, Ma R, Shen K · Pediatric Investigation · 2022 June
DOI 10.1002/ped4.12326
Objective
To evaluate the safety and efficacy of Yupingfeng (YPF) monotherapy in treating children with recurrent respiratory tract infection (RRTI).
Conclusions
Yupingfeng (YPF) granules were noninferior to the active control drug pidotimod oral solution for the treatment of RRTI in children, and were superior to placebo, with a high safety profile.
Critical Appraisal
Published research can offer valuable insights, but a paper’s conclusions may go beyond what its results support. Critical appraisal examines the methods, findings and limitations to clarify what can reasonably be concluded—and what remains uncertain.
This article has not yet been critically appraised by the Research Hub.
Learn more about Critical Appraisal
